Zacks Investment Research upgraded shares of Clinigen Group Plc (NASDAQ:CLIGF) from a hold rating to a buy rating in a research note published on Tuesday. Zacks Investment Research currently has $15.00 price objective on the stock.
According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
Shares of Clinigen Group Plc (NASDAQ CLIGF) traded up 7.34% during mid-day trading on Tuesday, reaching $13.90. 3,637 shares of the company’s stock traded hands. Clinigen Group Plc has a 12-month low of $8.70 and a 12-month high of $13.90. The company has a market cap of $1.60 billion and a P/E ratio of 85.80.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.